CA3115985A1 - Methods and formulations for treating chemotherapy-induced nausea and vomiting - Google Patents

Methods and formulations for treating chemotherapy-induced nausea and vomiting Download PDF

Info

Publication number
CA3115985A1
CA3115985A1 CA3115985A CA3115985A CA3115985A1 CA 3115985 A1 CA3115985 A1 CA 3115985A1 CA 3115985 A CA3115985 A CA 3115985A CA 3115985 A CA3115985 A CA 3115985A CA 3115985 A1 CA3115985 A1 CA 3115985A1
Authority
CA
Canada
Prior art keywords
formulation
day
patient
chemotherapy
thc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3115985A
Other languages
English (en)
French (fr)
Inventor
Catherine JACOBSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tilray Brands Inc
Original Assignee
Tilray Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tilray Inc filed Critical Tilray Inc
Publication of CA3115985A1 publication Critical patent/CA3115985A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3115985A 2018-10-10 2019-10-10 Methods and formulations for treating chemotherapy-induced nausea and vomiting Pending CA3115985A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862743839P 2018-10-10 2018-10-10
US62/743,839 2018-10-10
PCT/US2019/055662 WO2020077103A1 (en) 2018-10-10 2019-10-10 Methods and formulations for treating chemotherapy-induced nausea and vomiting

Publications (1)

Publication Number Publication Date
CA3115985A1 true CA3115985A1 (en) 2020-04-16

Family

ID=68345091

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3115985A Pending CA3115985A1 (en) 2018-10-10 2019-10-10 Methods and formulations for treating chemotherapy-induced nausea and vomiting

Country Status (12)

Country Link
US (1) US20200113847A1 (enExample)
EP (1) EP3863614A1 (enExample)
JP (1) JP2022502471A (enExample)
KR (1) KR20210116432A (enExample)
AU (1) AU2019357608A1 (enExample)
BR (1) BR112021006858A2 (enExample)
CA (1) CA3115985A1 (enExample)
CL (1) CL2021000882A1 (enExample)
CO (1) CO2021005797A2 (enExample)
MX (1) MX2021004138A (enExample)
PE (1) PE20211198A1 (enExample)
WO (1) WO2020077103A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3969054A4 (en) * 2019-05-16 2023-09-06 Aegis Therapeutics, LLC COMPOSITIONS CONTAINING OIL-SOLUBLE DRUGS AND METHODS OF USING SUCH COMPOSITIONS
JP7883957B2 (ja) 2020-05-18 2026-07-02 マックス バイオロジー カンパニー リミテッド 脂質ポリマー組成物及び使用方法
AU2021347760B2 (en) * 2020-09-24 2024-07-25 Nicoventures Trading Limited Formulation
US20240252464A1 (en) * 2022-07-06 2024-08-01 Avantsar Sdn Bhd A self-emulsifying drug delivery formulation with improved oral bioavailability of lipophilic compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US20040248970A1 (en) * 2003-04-10 2004-12-09 Webster G.R. Barrie CBD-delta8-THC composition
EP1706098A4 (en) * 2003-11-26 2012-08-15 Supernus Pharmaceuticals Inc MICRO-LAYER SYSTEMS FOR THE TRANSPORT OF LIPOPHILES AND BZW. HYDROPHOBIC COMPOUNDS
BRPI0610364A2 (pt) * 2005-05-13 2010-06-15 Unimed Pharmaceuticals Inc tratamento, com dronabinol, de náusea e vÈmito retardados induzidos por quimioterapia
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
RU2016129536A (ru) * 2013-10-31 2018-01-31 Фулл Спектрум Лабораториз, Лтд. Препараты на основе терпенов и каннабиноидов
WO2017203529A1 (en) * 2016-05-24 2017-11-30 Bol Pharma Ltd. Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
AU2017334283A1 (en) * 2016-09-27 2019-04-04 CannTab Therapeutics Limited Sustained release cannabinoid formulations
US20200163931A1 (en) * 2016-10-12 2020-05-28 Columbia Care Llc Oral composition of extracted cannabinoids and methods of use thereof
EA201991641A1 (ru) * 2017-01-03 2020-03-10 Ресептор Холдингз, Инк. Лекарственные соединения и пищевые добавки
WO2018152334A1 (en) * 2017-02-15 2018-08-23 Molecular Infusions, Llc Formulations
US10307392B2 (en) * 2017-10-21 2019-06-04 Alexander Kariman Compound and method for treatment of diseases and disorders
WO2019100007A1 (en) * 2017-11-17 2019-05-23 Tilray, Inc. Cannabinoid compositions
WO2019165387A1 (en) * 2018-02-23 2019-08-29 Spirtos Nicola Michael Cannabis based therapeutic and method of use
CA3107014A1 (en) * 2018-07-31 2020-02-06 AusCann Group Holdings Ltd Solid self-emulsifying pharmaceutical compositions

Also Published As

Publication number Publication date
KR20210116432A (ko) 2021-09-27
MX2021004138A (es) 2021-08-05
WO2020077103A1 (en) 2020-04-16
PE20211198A1 (es) 2021-07-01
US20200113847A1 (en) 2020-04-16
AU2019357608A1 (en) 2021-05-27
JP2022502471A (ja) 2022-01-11
CO2021005797A2 (es) 2021-05-20
BR112021006858A2 (pt) 2021-07-13
EP3863614A1 (en) 2021-08-18
CL2021000882A1 (es) 2021-08-27

Similar Documents

Publication Publication Date Title
US20200113847A1 (en) Methods and formulations for treating chemotherapy-induced nausea and vomiting
DK2600851T3 (en) PHARMACEUTICAL DOSAGE FORM CONTAINING 6'-FLUORO- (N-METHYL OR N, N-DIMETHYL -) - 4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO [CYCLOHEXAN-1,1'-PYRANO [3,4, B] INDOL] -4-AMINE FOR TREATMENT OF NEUROPATHIC PAIN
US20040110828A1 (en) Tetrahydrocannabinol compositions and methods of manufacture and use thereof
US20200368159A1 (en) Aqueous formulation for insoluble drugs
US20110033529A1 (en) Oral pharmaceutical paricalcitol formulations
EP2753336B1 (en) Compositions comprising s-adenosylmethionine and a gallic acid ester
US9872834B2 (en) Nanocarrier therapy for treating invasive tumors
US20260137626A1 (en) Pharmaceutical Formulation
US20040229939A1 (en) Tetrahydrocannabinol compositions and methods of manufacture and use thereof
US8263574B2 (en) Topical formulations for the treatment of depression with S adenosyl methionine
US10300017B2 (en) Method and composition for treating cystitis
CN118715010A (zh) 包含二苯基二唑衍生物的药物组合物及其使用方法
JP2025186249A (ja) リポソームカンナビノイドおよびその使用
CA3119786A1 (en) Cannabinoid compositions
US20200093787A1 (en) Cannabinoid Compositions
US20050249803A1 (en) Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
CN107281106B (zh) 胆酸盐修饰的阳离子维生素d3口服脂质体及其冻干制剂
WO2016084099A1 (en) Soft gelatin capsule composition of anti-tussive agents
US20060276436A1 (en) Farnesyl dibenzodiazepinone formulation
AU2023301386A1 (en) Pharmaceutical compositions comprising isotretinoin and processes for preparation and uses thereof
Blair et al. Liposomal cannabidiol delivery: A pilot study
WO2012066347A1 (en) Oil based formulations
WO2024130214A2 (en) Clofazimine mini-tablets for treatment of tuberculosis in pediatrics
HK40115748A (en) Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use
MX2015003810A (es) Metadoxina para usarse en el tratamiento de enfermedades hepaticas y formulaciones de liberacion prolongada de metadoxina.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220927

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250829

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251029

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251121

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260410